Xinovi announced that in the third quarter of 2026, it achieved operating income of 57.148 million yuan, a year-on-year decrease of 93.88%; net loss of 128 million yuan, a year-on-year decrease of 117.47%. The first three quarters of 2026 achieved operating income of 233 million yuan, a year-on-year decrease of 75.04%; net loss of 296 million yuan, a year-on-year decrease of 182.25%. R&D investment in the first three quarters was 464 million yuan, an increase of 30.34% over the previous year. R&D investment accounted for 199.05% of revenue. On September 14, 2026, the company's drug marketing license application for igmetostat maleate tablets was accepted by the State Drug Administration and included in the CDE priority review. The proposed indication was recurrent or refractory peripheral T-cell lymphoma.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.